Lisata Therapeutics to be Acquired by Kuva Labs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy LSTA?
Source: NASDAQ.COM
- Acquisition Agreement: Lisata Therapeutics has entered into a definitive acquisition agreement with Kuva Labs, which will purchase all outstanding shares at $5.00 each in cash, indicating strong recognition of Lisata's future potential.
- Contingent Value Rights: Each share will come with a contingent value right (CVR) that entitles holders to an additional $1.00 per share if a New Drug Application related to the candidate certepetide is accepted by the FDA within seven years, showcasing an incentive mechanism for successful R&D.
- Transaction Timeline: The transaction is expected to close in the second quarter of 2026, after which Lisata will become part of Kuva Labs and will be delisted from the Nasdaq Capital Market, marking a significant strategic restructuring for the company.
- Stock Price Fluctuation: Lisata closed at $4.18 last Friday, down 1.18%, but surged to $4.99 in after-hours trading, a 19.38% increase, reflecting the market's positive reaction to the acquisition news.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LSTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LSTA
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lisata Therapeutics to be Acquired by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics has entered into a definitive acquisition agreement with Kuva Labs, which will purchase all outstanding shares at $5.00 each in cash, indicating strong recognition of Lisata's future potential.
- Contingent Value Rights: Each share will come with a contingent value right (CVR) that entitles holders to an additional $1.00 per share if a New Drug Application related to the candidate certepetide is accepted by the FDA within seven years, showcasing an incentive mechanism for successful R&D.
- Transaction Timeline: The transaction is expected to close in the second quarter of 2026, after which Lisata will become part of Kuva Labs and will be delisted from the Nasdaq Capital Market, marking a significant strategic restructuring for the company.
- Stock Price Fluctuation: Lisata closed at $4.18 last Friday, down 1.18%, but surged to $4.99 in after-hours trading, a 19.38% increase, reflecting the market's positive reaction to the acquisition news.
See More
Lisata Therapeutics to be Acquired by Kuva Labs for $5.00 per Share
- Acquisition Details: Kuva Labs will acquire all outstanding shares of Lisata Therapeutics for $5.00 per share in cash, plus a contingent value right of $1.00 per share if FDA approval is obtained for certain drug applications, with the transaction expected to close in Q2 2026, marking a significant transition for Lisata.
- Board Recommendation: Following a thorough evaluation, Lisata's board unanimously determined that the merger agreement is fair and in the best interests of shareholders, authorizing the execution of the agreement and strongly recommending that shareholders accept the offer, reflecting confidence in future growth.
- Market Impact Analysis: The acquisition will result in Lisata becoming a private entity, leading to its delisting from Nasdaq, which may affect investor liquidity and market confidence, while providing Kuva Labs an opportunity to enter the clinical-stage pharmaceutical market.
- Strategic Significance: Lisata's core product, certepetide, aims to enhance cancer treatment, and the acquisition by Kuva Labs will integrate both companies' technological strengths, driving the development of innovative therapies and enhancing competitiveness in the biopharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may involve violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company's merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined company, with Halper Sadeh LLC assessing the fairness of the transaction and its impact on shareholders.
- Cash Acquisition Analysis: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights, raising concerns from Halper Sadeh LLC about whether this transaction serves the best interests of shareholders.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, with Halper Sadeh LLC investigating the potential implications and protections for shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company’s merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined entity, and Halper Sadeh LLC may seek increased consideration and additional disclosures.
- Cash Acquisition Scrutiny: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable rights, and Halper Sadeh LLC is assessing whether this transaction aligns with shareholder interests.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning about 80.3% of the combined company, with Halper Sadeh LLC potentially advocating for higher transaction consideration and additional shareholder benefits.
See More
Investor Rights Law Firm Investigates Multiple Companies
- SkyWater Transaction Investigation: Halper Sadeh LLC is investigating SkyWater Technology, Inc. (NASDAQ: SKYT) for its sale to IonQ at $15.00 in cash and $20.00 in IonQ common stock, potentially violating federal securities laws and fiduciary duties to shareholders.
- Nathan's Famous Sale Review: The firm is also scrutinizing Nathan’s Famous, Inc. (NASDAQ: NATH) for its sale to Smithfield Foods, Inc. at $102.00 per share in cash, which may impact shareholder rights.
- Sun Country Airlines Deal Issues: The sale of Sun Country Airlines Holdings, Inc. (NASDAQ: SNCY) to Allegiant Travel Company for 0.1557 shares of Allegiant common stock and $4.10 in cash per share is under investigation, with the firm potentially seeking increased compensation for shareholders.
- Lisata Therapeutics Transaction Focus: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being reviewed for its sale to Kuva Labs, Inc. at $4.00 per share in cash plus two non-tradeable contingent value rights, with the law firm offering legal support to shareholders.
See More
Investigations Launched into Multiple Company Acquisitions
- SkyWater Acquisition Investigation: SkyWater Technology is set to be acquired by IonQ for $35 per share, totaling approximately $1.8 billion; however, this price is below the company's 52-week high of $36.27, raising concerns about shareholder value.
- Nathan's Famous Deal Scrutiny: Nathan's Famous will be acquired by Smithfield Foods for $102 per share, representing an enterprise value of about $450 million, yet this price is below its 52-week high of $118.50, prompting questions about the board's fiduciary duties.
- Lisata Therapeutics Merger Issues: Lisata Therapeutics will be acquired by Kuva Labs for $4 per share, plus two non-tradeable rights, with investigations focusing on whether the board failed to conduct a fair process, potentially harming shareholder interests.
- Sun Country Airlines Acquisition Review: Sun Country Airlines will be acquired for 0.1557 shares of Allegiant stock and $4.10 in cash per share, implying a value of $18.89 per share, with investigations into whether the board breached its fiduciary duties to shareholders.
See More
Lisata Therapeutics to be Acquired by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics has entered into a definitive acquisition agreement with Kuva Labs, which will purchase all outstanding shares at $5.00 each in cash, indicating strong recognition of Lisata's future potential.
- Contingent Value Rights: Each share will come with a contingent value right (CVR) that entitles holders to an additional $1.00 per share if a New Drug Application related to the candidate certepetide is accepted by the FDA within seven years, showcasing an incentive mechanism for successful R&D.
- Transaction Timeline: The transaction is expected to close in the second quarter of 2026, after which Lisata will become part of Kuva Labs and will be delisted from the Nasdaq Capital Market, marking a significant strategic restructuring for the company.
- Stock Price Fluctuation: Lisata closed at $4.18 last Friday, down 1.18%, but surged to $4.99 in after-hours trading, a 19.38% increase, reflecting the market's positive reaction to the acquisition news.
See More
Lisata Therapeutics to be Acquired by Kuva Labs for $5.00 per Share
- Acquisition Details: Kuva Labs will acquire all outstanding shares of Lisata Therapeutics for $5.00 per share in cash, plus a contingent value right of $1.00 per share if FDA approval is obtained for certain drug applications, with the transaction expected to close in Q2 2026, marking a significant transition for Lisata.
- Board Recommendation: Following a thorough evaluation, Lisata's board unanimously determined that the merger agreement is fair and in the best interests of shareholders, authorizing the execution of the agreement and strongly recommending that shareholders accept the offer, reflecting confidence in future growth.
- Market Impact Analysis: The acquisition will result in Lisata becoming a private entity, leading to its delisting from Nasdaq, which may affect investor liquidity and market confidence, while providing Kuva Labs an opportunity to enter the clinical-stage pharmaceutical market.
- Strategic Significance: Lisata's core product, certepetide, aims to enhance cancer treatment, and the acquisition by Kuva Labs will integrate both companies' technological strengths, driving the development of innovative therapies and enhancing competitiveness in the biopharmaceutical sector.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may involve violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company's merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined company, with Halper Sadeh LLC assessing the fairness of the transaction and its impact on shareholders.
- Cash Acquisition Analysis: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable contingent value rights, raising concerns from Halper Sadeh LLC about whether this transaction serves the best interests of shareholders.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning approximately 80.3% of the combined entity, with Halper Sadeh LLC investigating the potential implications and protections for shareholder rights.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc.'s sale to GSK plc for $58.00 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: Allegiant Travel Company’s merger with Sun Country Airlines will result in Allegiant shareholders owning approximately 67% of the combined entity, and Halper Sadeh LLC may seek increased consideration and additional disclosures.
- Cash Acquisition Scrutiny: Lisata Therapeutics, Inc. is being sold to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable rights, and Halper Sadeh LLC is assessing whether this transaction aligns with shareholder interests.
- Equity Distribution in Merger: The merger between Mission Produce, Inc. and Calavo Growers, Inc. is expected to result in Mission shareholders owning about 80.3% of the combined company, with Halper Sadeh LLC potentially advocating for higher transaction consideration and additional shareholder benefits.
See More
Investor Rights Law Firm Investigates Multiple Companies
- SkyWater Transaction Investigation: Halper Sadeh LLC is investigating SkyWater Technology, Inc. (NASDAQ: SKYT) for its sale to IonQ at $15.00 in cash and $20.00 in IonQ common stock, potentially violating federal securities laws and fiduciary duties to shareholders.
- Nathan's Famous Sale Review: The firm is also scrutinizing Nathan’s Famous, Inc. (NASDAQ: NATH) for its sale to Smithfield Foods, Inc. at $102.00 per share in cash, which may impact shareholder rights.
- Sun Country Airlines Deal Issues: The sale of Sun Country Airlines Holdings, Inc. (NASDAQ: SNCY) to Allegiant Travel Company for 0.1557 shares of Allegiant common stock and $4.10 in cash per share is under investigation, with the firm potentially seeking increased compensation for shareholders.
- Lisata Therapeutics Transaction Focus: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being reviewed for its sale to Kuva Labs, Inc. at $4.00 per share in cash plus two non-tradeable contingent value rights, with the law firm offering legal support to shareholders.
See More
Investigations Launched into Multiple Company Acquisitions
- SkyWater Acquisition Investigation: SkyWater Technology is set to be acquired by IonQ for $35 per share, totaling approximately $1.8 billion; however, this price is below the company's 52-week high of $36.27, raising concerns about shareholder value.
- Nathan's Famous Deal Scrutiny: Nathan's Famous will be acquired by Smithfield Foods for $102 per share, representing an enterprise value of about $450 million, yet this price is below its 52-week high of $118.50, prompting questions about the board's fiduciary duties.
- Lisata Therapeutics Merger Issues: Lisata Therapeutics will be acquired by Kuva Labs for $4 per share, plus two non-tradeable rights, with investigations focusing on whether the board failed to conduct a fair process, potentially harming shareholder interests.
- Sun Country Airlines Acquisition Review: Sun Country Airlines will be acquired for 0.1557 shares of Allegiant stock and $4.10 in cash per share, implying a value of $18.89 per share, with investigations into whether the board breached its fiduciary duties to shareholders.
See More
